Identifying a novel target for cancer immunotherapy

April 12, 2017 by Anna Williams

Targeting a molecule called B7-H4—which blocks T-cells from destroying tumor cells—could lead to the development of new therapies that boost the immune system's ability to fight cancer, according to a review published in the journal Immunological Reviews.

"Targeting B7-H4 itself, or in combination with the current therapies, may lead to more effective treatments for a variety of cancers," said Stephen Miller, PhD, the Judy Gugenheim Research Professor of Microbiology-Immunology and of Dermatology, the lead author of the paper. Joseph Podojil, PhD, research associate professor of Microbiology-Immunology, was the first author.

Immunotherapy is a type of treatment that stimulates the patient's own immune system to attack . One immunotherapy approach involves targeting a group of proteins, called immune checkpoints, that normally prevents the immune system from attacking tumor . By employing antibodies that specifically block the checkpoints, these drugs unlock the "breaks" on the immune system, freeing T-cells to detect and destroy .

"Cancer therapy has recently been revolutionized with this approach," said Miller, also director of the Interdepartmental Immunobiology Center. "However, the two checkpoint-inhibitor blockers currently used only work in a minority of patients with a particular cancer, and not at all in other forms. Additional checkpoint inhibitors need to be identified and blocked in order to enhance the therapeutic response rate in ."

In the review, Miller and Podojil highlight the potential of targeting B7-H4, a more recently discovered immune-inhibitory protein.

Miller's lab had previously studied B7-H4—and the mechanisms by which it thwarts the immune response—in the context of a treatment for multiple sclerosis, an autoimmune disease. Other research has also shown that B7-H4 is overexpressed in many types of tumors, and high levels are linked to adverse outcomes in cancer patients.

While blocking B7-H4 has not yet been clinically tested—and its actual effectiveness in is not yet known—the authors note that much of the existing data point to B7-H4 as a promising target for new immunotherapies that may treat a wider range of cancers.

Explore further: Patients' immune system may influence effectiveness of cancer immunotherapy

More information: Joseph R. Podojil et al. Potential targeting of B7-H4 for the treatment of cancer, Immunological Reviews (2017). DOI: 10.1111/imr.12530

Related Stories

Researchers identify new target for cancer immunotherapy

January 17, 2017

Massachusetts General Hospital investigators have found new evidence that the tumor necrosis factor receptor type II (TNFR2) may be a major target for immuno-oncology treatments, which induce a patient's immune system to ...

Researchers take step toward eliminating cancer recurrence

September 1, 2016

Scientists from the United States have made an important step toward eliminating cancer recurrence by combining immunotherapy with chemotherapy. Specifically, they found that chemotherapy alone leads to two types of dormant ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.